Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia With Ibrutinib

Clinical Cancer Research- United States

doi 10.1158/1078-0432.ccr-15-3106

Full Text

Abstract

Available in

Categories

Cancer Research

Date

February 4, 2016

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Cancer therapy & Oncology International Journal

English

Ibrutinib Therapy Releases Leukemic Surface IgM From Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Clinical Cancer Research

Cancer Research

English

Anticoagulant Therapy in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib

Hematological Oncology

Cancer Research

English

Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib

Cancer Research

English

Amebic Encephalitis in a Patient With Chronic Lymphocytic Leukemia on Ibrutinib Therapy

Case Reports in Hematology

English

Successful Treatment of Chronic Lymphocytic Leukemia Mutlifocal Central Nervous System Involvement With Ibrutinib

Turkish Journal of Haematology

English

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Medical Council

English

Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

Clinical Cancer Research

Cancer Research

English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology

Cancer Research

English